



**INTERNATIONAL JOURNAL OF  
PHARMACEUTICAL SCIENCES**  
[ISSN: 0975-4725; CODEN(USA): IJPS00]  
Journal Homepage: <https://www.ijpsjournal.com>



## Review Article

# Leveraging Artificial Intelligence for Enhanced Pharmacy Practice: A Comprehensive Review

Abhijit Dongardive\*<sup>1</sup>, Salman Khan<sup>2</sup>, Sagar Sirsat<sup>3</sup>, Trupti Kokane<sup>4</sup>, Akshay Jagtap<sup>5</sup>

<sup>1,2,4</sup>Department of Pharmaceutical Chemistry, Kamalprakash Pharmacy College and Research Centre, Kherda, Karanja (Lad) Dist. Washim, Maharashtra India-444107.

<sup>3,5</sup>Department of Pharmacy Pharmacology, Narendra Suryavanshi College of Pharmacy Kelzer, Wardha-442104.

## ARTICLE INFO

Received: 29 June 2024

Accepted: 02 June 2024

Published: 12 July 2024

### Keywords:

Artificial intelligence (AI), Drug discovery and development, Medication optimization, Clinical decision support, supply chain management.

### DOI:

10.5281/zenodo.12733016

## ABSTRACT

Artificial intelligence (AI) has emerged as a transformative technology in healthcare, revolutionizing various aspects of pharmacy practice. This comprehensive review explores the applications, benefits, challenges, and future prospects of AI in pharmacy settings. Firstly, the review delves into AI's role in medication optimization, wherein AI-powered systems analyze patient data, including medical history, genetic information, and treatment outcomes, to personalize medication regimens and optimize dosages for improved efficacy and reduced side effects. Additionally, AI facilitates clinical decision support by providing real-time insights and recommendations to clinicians and pharmacists regarding medication therapy, drug interactions, and adverse reactions. AI algorithms are instrumental in drug discovery and development, accelerating research processes, improving success rates, and reducing costs. By leveraging computational methods and predictive modeling, AI enhances target identification, drug design, virtual screening, lead optimization, and clinical trial optimization.

## INTRODUCTION

Artificial intelligence (AI) is revolutionizing various industries, and pharmacy is no exception. In pharmacy, AI refers to the use of advanced algorithms and machine learning techniques to analyze vast amounts of data and improve various aspects of medication management, patient care,

drug discovery, and pharmacy operations.<sup>1</sup> Despite the numerous benefits, the adoption of AI in pharmacy faces challenges related to data privacy, regulatory compliance, interoperability, integration with existing systems, and workforce training. However, overcoming these challenges presents opportunities for innovative solutions and

\*Corresponding Author: Abhijit Dongardive

Address: Department of Pharmaceutical Chemistry, Kamalprakash Pharmacy College and Research Centre, Kherda, Karanja (Lad) Dist. Washim, Maharashtra India-444107

Email ✉: [dongardiveabhijit@gmail.com](mailto:dongardiveabhijit@gmail.com)

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



collaborative partnerships between healthcare stakeholders, technology providers, and regulatory agencies.<sup>2</sup> The integration of AI in pharmacy holds the promise of enhancing efficiency, accuracy, and safety throughout the medication use process.<sup>3</sup>

From optimizing drug discovery pipelines to personalizing medication regimens for individual patients, AI-powered solutions are reshaping how pharmacists, clinicians, and patients interact with pharmaceuticals.<sup>4</sup> In this introduction to artificial intelligence in pharmacy, we'll explore some key applications and benefits of AI in the field, including:

**Drug discovery and development:** AI algorithms can analyze large datasets to identify potential drug candidates, predict their properties, and streamline the drug development process, leading to faster and more cost-effective discoveries.<sup>5</sup>

**Medication optimization:** AI-powered systems can analyze patient data, including medical history, genetic information, and treatment outcomes, to personalize medication regimens and optimize dosages for better efficacy and reduced side effects.<sup>6</sup>

**Clinical decision support:** AI-based decision support tools provide clinicians and pharmacists with real-time insights and recommendations, helping them make informed decisions about medication therapy, drug interactions, and adverse reactions.<sup>7</sup>

**Pharmacy operations and supply chain management:** AI algorithms can optimize inventory management, predict medication demand, and streamline logistics, ensuring efficient pharmaceutical supply chains and reducing waste and costs.<sup>8</sup>

**Patient engagement and adherence:** AI-driven mobile apps and virtual assistants can educate patients about their medications, remind them to take their doses, and provide support for medication adherence, leading to improved health outcomes and reduced hospitalizations.<sup>8</sup>

### **Drug discovery and development**

Drug discovery and development is a complex and costly process that typically takes years and

involves numerous steps, from target identification to clinical trials. Artificial intelligence (AI) is revolutionizing this process by accelerating research, improving success rates, and reducing costs.<sup>9</sup>

Here's how AI is transforming drug discovery and development:

**Target identification and validation:** AI algorithms can analyze vast amounts of biological data, including genomics, proteomics, and literature, to identify potential drug targets with high therapeutic potential. By prioritizing targets based on their relevance to disease mechanisms, AI speeds up the early stages of drug discovery.<sup>10</sup>

**Drug design and optimization:** AI-powered computational methods, such as machine learning and deep learning, enable researchers to design and optimize novel drug candidates more efficiently. These algorithms can predict the chemical properties, pharmacokinetics, and safety profiles of potential drugs, helping researchers prioritize the most promising candidates for further testing.<sup>11 12</sup>

**Virtual screening and lead optimization:** AI algorithms can perform virtual screening of chemical libraries to identify compounds with the desired biological activity against a target. By simulating interactions between molecules and biological targets, AI accelerates the identification of lead compounds and their optimization for improved efficacy and safety.<sup>13</sup>

**Prediction of drug-drug interactions and toxicity:** AI models can predict potential drug-drug interactions and adverse effects by analyzing molecular structures, biological pathways, and clinical data. These predictions help researchers prioritize drug candidates with lower risks of side effects and toxicity, reducing the likelihood of safety issues during clinical development.<sup>14</sup>

**Clinical trial optimization:** AI algorithms can analyze patient data and clinical trial results to identify biomarkers, patient subpopulations, and optimal trial designs. By optimizing patient



selection criteria and trial protocols, AI enhances the efficiency and success rates of clinical trials, leading to faster drug approvals and reduced development costs.<sup>15</sup>

**Repurposing existing drugs:** AI-driven drug repurposing platforms analyze large datasets of drug compounds and biological targets to identify new therapeutic uses for existing drugs. By leveraging existing safety and pharmacokinetic data, AI accelerates the identification of potential drug candidates for repurposing, reducing the time and costs associated with traditional drug discovery.<sup>16</sup>

### **Medication optimization**

**Personalized Medicine:** AI algorithms analyze various patient data, including medical history, genetic information, lifestyle factors, and treatment outcomes, to create individualized medication regimens tailored to each patient's unique characteristics. By considering a patient's genetic predispositions and physiological responses to medications, AI can optimize treatment plans for better efficacy and reduced side effects.<sup>17</sup> **Predictive Modeling:** AI can predict how patients are likely to respond to different medications and dosages based on their demographic information, medical history, genetic profile, and other relevant factors. By analyzing large datasets of patient outcomes, AI algorithms identify patterns and correlations that help predict the most effective treatment options for specific patient populations.<sup>18</sup> **Optimization of Dosages:** AI-powered systems can optimize medication dosages based on factors such as age, weight, kidney function, liver function, drug interactions, and genetic variations in drug metabolism pathways.<sup>19</sup> By considering these factors, AI can recommend personalized dosing regimens that maximize therapeutic benefits while minimizing the risk of adverse reactions or toxicity.<sup>20</sup>

**Real-Time Monitoring:** AI-enabled monitoring systems can track patient responses to medications

in real time, using data from wearable devices, electronic health records, and other sources. By continuously analyzing patient data, AI algorithms can adjust medication regimens as needed to optimize outcomes and prevent complications.<sup>21 22</sup>

**Clinical Decision Support:** AI-based clinical decision support tools provide healthcare providers with real-time recommendations and alerts regarding medication selection, dosing, monitoring, and adjustments. By integrating with electronic health records and other clinical systems, AI helps clinicians make more informed decisions about medication therapy, leading to improved patient outcomes and safety.<sup>23</sup>

### **Clinical decision support**

**Real-time Insights:** AI-based CDS tools continuously analyze patient data, including medical history, lab results, medication records, and diagnostic information, to provide clinicians and pharmacists with real-time insights into patient care. By processing large volumes of data quickly and accurately, AI helps healthcare providers make informed decisions about medication therapy and treatment plans.<sup>24</sup>

**Medication Therapy:** AI-based CDS systems help clinicians and pharmacists select the most appropriate medications for individual patients based on their medical conditions, allergies, comorbidities, and other relevant factors. These systems can recommend evidence-based treatment guidelines, drug formularies, and alternative therapies to optimize medication therapy and improve patient outcomes.<sup>25</sup>

**Drug Interactions:** AI algorithms analyze medication lists and patient data to identify potential drug-drug interactions, contraindications, and adverse reactions.<sup>26</sup> By flagging potential risks and providing recommendations for alternative medications or dosage adjustments, AI-based CDS tools help prevent medication errors and adverse drug events.<sup>1</sup>

**Adverse Reactions:** AI-powered CDS systems can detect early signs of adverse drug



reactions and alert healthcare providers to potential safety concerns.<sup>27</sup> By monitoring patient responses to medications and

Correlating symptoms with drug exposures, AI helps clinicians and pharmacists intervene promptly to mitigate risks and ensure patient safety.<sup>28</sup> Clinical Guidelines Compliance: AI-based CDS tools help healthcare providers adhere to evidence-based clinical guidelines and best practices by integrating clinical decision rules, treatment protocols, and quality measures into their workflow.<sup>29</sup> By aligning care delivery with established standards, AI improves the consistency and quality of patient care across healthcare settings.<sup>30</sup> Efficiency and Workflow Integration: AI-powered CDS systems seamlessly integrate into existing clinical workflows, electronic health record systems, and pharmacy management systems, providing clinicians and pharmacists with actionable insights and recommendations at the point of care. By streamlining decision-making processes and reducing cognitive burden, AI enhances efficiency and productivity in healthcare delivery.<sup>31</sup>

### **Pharmacy operations and supply chain management**

**Inventory Management Optimization:** AI-powered systems analyze historical sales data, seasonal trends, and patient demand patterns to optimize inventory levels and ensure that pharmacies have the right medications in stock at the right time. By predicting future demand and adjusting inventory levels accordingly, AI minimizes stockouts, reduces excess inventory, and improves overall inventory turnover rates.<sup>32</sup> **Demand Forecasting:** AI algorithms use advanced forecasting techniques to predict medication demand based on factors such as demographic trends, population health indicators, and healthcare utilization patterns. By accurately forecasting future demand, AI helps pharmacies anticipate supply needs, optimize procurement decisions, and prevent shortages or

overstock situations.<sup>33</sup> **Supply Chain Logistics:** AI streamlines the logistics of pharmaceutical supply chains by optimizing transportation routes, scheduling deliveries, and coordinating inventory replenishment across multiple distribution centers and pharmacy locations. By optimizing logistics operations, AI reduces transportation costs, minimizes delivery times, and improves overall supply chain efficiency.<sup>34</sup> **Vendor Management:** AI-powered systems analyze vendor performance data, pricing trends, and contract terms to optimize vendor selection, negotiate favorable terms, and ensure compliance with contractual agreements. By identifying the most cost-effective suppliers and maintaining strong vendor relationships, AI helps pharmacies reduce procurement costs and mitigate supply chain risks.<sup>35</sup> **Quality Control and Compliance:** AI algorithms monitor product quality, track expiration dates, and identify potential counterfeit medications or regulatory compliance issues within the supply chain. By implementing real-time monitoring and automated quality control checks, AI helps pharmacies maintain high standards of product safety and regulatory compliance throughout the supply chain.<sup>16</sup> **Predictive Maintenance:** AI-enabled predictive maintenance systems monitor pharmacy equipment and infrastructure, such as refrigeration units and automated dispensing systems, to detect potential failures or malfunctions before they occur. By proactively identifying maintenance needs and scheduling repairs or replacements, AI minimizes downtime, reduces maintenance costs, and ensures uninterrupted pharmacy operations.<sup>36</sup>

### **CONCLUSION**

The integration of artificial intelligence (AI) into pharmacy practice offers a plethora of benefits that can significantly enhance patient care, optimize workflow efficiency, and improve medication management processes. Through advanced algorithms and machine learning techniques, AI



can analyze vast amounts of data, identify patterns, and provide valuable insights to pharmacists and healthcare professionals. Furthermore, leveraging artificial intelligence in pharmacy practice holds immense promise for transforming the way medications are prescribed, dispensed, and managed. By harnessing the power of AI, pharmacists can enhance patient outcomes, improve operational efficiency, and drive innovation in the field of healthcare. As technology continues to evolve, the role of AI in pharmacy practice will undoubtedly become increasingly indispensable, paving the way for a future where personalized, data-driven care is the norm.

#### Conflict of Interest:

The authors declare that there is a no conflict of Interest.

#### REFERENCE

- Price, W. N. (2017). Regulating Black-Box medicine. *Michigan Law Review*, 116.3, 421. <https://doi.org/10.36644/mlr.116.3.regulatin>
- Primorac, D., Bach-Rojecky, L., Vađunec, D., Juginović, A., Žunić, K., Matišić, V., Skelin, A., Arsov, B., Boban, L., Erceg, D., Ivkošić, I. E., Molnar, V., Čatić, J., Mikula, I., Boban, L., Primorac, L., Esquivel, B., & Donaldson, M. (2020). Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of Big Data. *Pharmacogenomics*, 21(2), 141–156. <https://doi.org/10.2217/pgs-2019-0134>
- Fleming, K. A., Horton, S., Wilson, M. L., Atun, R., DeStigter, K. K., Flanigan, J., Sayed, S., Adam, P., Aguilar, B., Andronikou, S., Boehme, C., Cherniak, W., Cheung, A. N. Y., Dahn, B., Donoso-Bach, L., Douglas, T. S., García, P. R., Hussain, S., Iyer, H. S., . . . Walia, K. (2021). The Lancet Commission on diagnostics: transforming access to diagnostics. *Lancet*, 398(10315), 1997–2050. [https://doi.org/10.1016/s0140-6736\(21\)00673-5](https://doi.org/10.1016/s0140-6736(21)00673-5)
- Khan, N., Qureshi, M. I., Mustapha, I., Irum, S., & Arshad, R. N. (2020). A Systematic Literature Review Paper on Online Medical Mobile Applications in Malaysia. *International Journal of Online and Biomedical Engineering*, 16(01), 63. <https://doi.org/10.3991/ijoe.v16i01.12263>
- Rasheed, A., San, O., & Kvamsdal, T. (2020). Digital Twin: values, challenges and enablers from a modeling perspective. *IEEE Access*, 8, 21980–22012. <https://doi.org/10.1109/access.2020.2970143>
- Boulos, M. N. K., Wilson, J. T., & Clauson, K. A. (2018). Geospatial blockchain: promises, challenges, and scenarios in health and healthcare. *International Journal of Health Geographics*, 17(1). <https://doi.org/10.1186/s12942-018-0144-x>
- Su, Z., He, L., Jariwala, S., Zheng, K., & Chen, Y. (2022). “What is Your Envisioned Future?”: Toward Human-AI Enrichment in Data Work of Asthma Care. *Proceedings of the ACM on Human-computer Interaction*, 6(CSCW2), 1–28. <https://doi.org/10.1145/3555157>
- Ejiyi, C. J., Qin, Z., Ejiyi, M. B., Nneji, G. U., Monday, H. N., Agu, F. A., Ejiyi, T. U., Diokpo, C. N., & Orakwue, C. O. (2023a). The internet of medical things in healthcare management: a review. *Journal of Digital Health*, 30–62. <https://doi.org/10.55976/jdh.22023116330-62>
- Ahmad, Z., Rahim, S., Zubair, M., & Abdul-Ghafar, J. (2021). Artificial intelligence (AI) in medicine, current applications and future role with special emphasis on its potential and promise in pathology: present and future impact, obstacles including costs and acceptance among pathologists, practical and



- philosophical considerations. A comprehensive review. *Diagnostic Pathology*, 16(1). <https://doi.org/10.1186/s13000-021-01085-4>
10. Coley, C. W., Eyke, N. S., & Jensen, K. F. (2020). Autonomous Discovery in the Chemical Sciences Part I: Progress. *Angewandte Chemie*, 59(51), 22858–22893. <https://doi.org/10.1002/anie.201909987>
  11. Selvaraj, C., Chandra, I., & Singh, S. K. (2021). Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries. *Molecular Diversity*, 26(3), 1893–1913. <https://doi.org/10.1007/s11030-021-10326-z>
  12. Beilmann, M. (2018). Optimizing drug discovery by Investigative Toxicology: Current and future trends. *ALTEX/Alternatives to Animal Experimentation*. <https://doi.org/10.14573/altex.1808181>
  13. Tsaramirsis, G., Kantaros, A., Al-Darraj, I., Piromalis, D., Apostolopoulos, C., Pavlopoulou, A., Alrammal, M., Ismail, Z., Buhari, S. M., Stojmenović, M., Tamimi, H., Randhawa, P., Patel, A., & Khan, F. Q. (2022). A Modern Approach towards an Industry 4.0 Model: From Driving Technologies to Management. *Journal of Sensors*, 2022, 1–18. <https://doi.org/10.1155/2022/5023011>
  14. Seyhan, A. A., & Carini, C. (2019). Are innovation and new technologies in precision medicine paving a new era in patients centric care? *Journal of Translational Medicine*, 17(1). <https://doi.org/10.1186/s12967-019-1864-9>
  15. Fountzilias, E., Tsimberidou, A. M., Vo, H. H., & Kurzrock, R. (2022). Clinical trial design in the era of precision medicine. *Genome Medicine*, 14(1). <https://doi.org/10.1186/s13073-022-01102-1>
  16. Tagde, P., Tagde, S., Bhattacharya, T., Tagde, P., Chopra, H., Akter, R., Kaushik, D., & Rahman, M. H. (2021). Blockchain and artificial intelligence technology in e-Health. *Environmental Science and Pollution Research International*, 28(38), 52810–52831. <https://doi.org/10.1007/s11356-021-16223-0>
  17. Wang, R., & Wang, Z. (2023). Precision Medicine: disease subtyping and tailored treatment. *Cancers*, 15(15), 3837. <https://doi.org/10.3390/cancers15153837>
  18. Singh, A., Chandrasekar, V., Paudel, N., Laux, P., Luch, A., Gemmati, D., Tissato, V., Prabhu, K. S., Uddin, S., & Dakua, S. P. (2023). Integrative toxicogenomics: Advancing precision medicine and toxicology through artificial intelligence and OMICs technology. *Biomedicine & Pharmacotherapy*, 163, 114784. <https://doi.org/10.1016/j.biopha.2023.114784>
  19. Kones, R. (2011). Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. *Drug Design, Development and Therapy*, 325. <https://doi.org/10.2147/dddt.s14934>
  20. Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M., Bergler-Klein, J., Boriani, G., Cardinale, D., Córdoba, R., Cosyns, B., Cutter, D. J., De Azambuja, E., De Boer, R. A., Dent, S., Farmakis, D., Gevaert, S., Gorog, D. A., Herrmann, J., Lenihan, D. J., . . . Czuriga, D. (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-

- Oncology Society (IC-OS). *European Heart Journal*, 43(41), 4229–4361. <https://doi.org/10.1093/eurheartj/ehac244>
21. Basevi, V. (2011). Standards of Medical Care in Diabetes—2011. *Diabetes Care*, 34(Supplement\_1), S11–S61. <https://doi.org/10.2337/dc11-s011>
  22. Ding, X., Clifton, D. A., Ji, N., Lovell, N. H., Bonato, P., Chen, W., Yu, X., Xue, Z., Xiang, T., Long, X., Xu, K., Jiang, X., Wang, Q., Yin, B., Feng, G., & Zhang, Y. (2021). Wearable Sensing and Telehealth Technology with Potential Applications in the Coronavirus Pandemic. *IEEE Reviews in Biomedical Engineering*, 14, 48–70. <https://doi.org/10.1109/rbme.2020.2992838>
  23. Choudhury, A., & Asan, O. (2020). Role of Artificial Intelligence in patient Safety Outcomes: Systematic Literature review. *JMIR Medical Informatics*, 8(7), e18599. <https://doi.org/10.2196/18599>
  24. Romero-Brufau, S., Wyatt, K. D., Boyum, P., Mickelson, M., Moore, M., & Cognetta-Rieke, C. (2020). A lesson in implementation: A pre-post study of providers' experience with artificial intelligence-based clinical decision support. *International Journal of Medical Informatics*, 137, 104072. <https://doi.org/10.1016/j.ijmedinf.2019.104072>
  25. Abstracts from the 21st Annual HMO Research Network Conference, March 11–13, 2015, Long Beach, California. (2015). *Journal of Patient-centered Research and Reviews*, 2(2), 78–141. <https://doi.org/10.17294/2330-0698.1201>
  26. Abacha, A. B., & Demner-Fushman, D. (2019). A question-entailment approach to question answering. *BMC Bioinformatics*, 20(1). <https://doi.org/10.1186/s12859-019-3119-4>
  27. Orlando, J. P., Firstenberg, M. S., Stawicki, S. P., Bayram, S., Çalışkan, N., Domer, G. S., Gallagher, T., Shahabzada, S., Sotherland, J., Paul, É., Kumar, K., Wilson, B., Salpekar, S., Kaur, P., Van Den Goor, M., Bondarouk, T., Otokiti, A., Morgan, T. L., Konerth, S., & Gaonkar, P. (2022). Contemporary Topics in Patient Safety - Volume 1. In *IntechOpen eBooks*. <https://doi.org/10.5772/intechopen.87616>
  28. Wang, L. (2021). *Autonomy vs. artificial intelligence : studies on healthcare work and analytics*. <https://doi.org/10.32657/10356/146910>
  29. Mahadevaiah, G., Rv, P., Bermejo, I., Jaffray, D. A., Dekker, A., & Wee, L. (2020). Artificial intelligence-based clinical decision support in modern medical physics: Selection, acceptance, commissioning, and quality assurance. *Medical Physics on CD-ROM/Medical Physics*, 47(5). <https://doi.org/10.1002/mp.13562>
  30. Rasheed, A., San, O., & Kvamsdal, T. (2020). Digital Twin: values, challenges and enablers from a modeling perspective. *IEEE Access*, 8, 21980–22012. <https://doi.org/10.1109/access.2020.297014>
  31. Yang, P., Gao, W., Pursch, M., & Luong, J. (2022). Gaining new insights in advanced polymeric materials using comprehensive Two-Dimensional Liquid Chromatography. *LC GC North America*, 186–189. <https://doi.org/10.56530/lcgc.na.xh1183h9>
  32. Mestiyage, R. D. (2022). *Framework for embedding optimisation and simulation tools in supply chain management*. <https://doi.org/10.7190/shu-thesis-00474>
  33. Dash, S., Shakyawar, S. K., Sharma, M., & Kaushik, S. (2019). Big data in healthcare: management, analysis and future prospects. *Journal of Big Data*, 6(1). <https://doi.org/10.1186/s40537-019-0217-0>



34. AbuKhoua, E., Al-Jaroodi, J., Lazarova-Molnar, S., & Mohamed, N. (2014). Simulation and modeling efforts to support decision making in healthcare supply chain management. *the Scientific World Journal/TheScientificWorldjournal*, 2014, 1–16. <https://doi.org/10.1155/2014/354246>
35. Meyers, S. (1998). *Improving energy efficiency: Strategies for supporting sustained market evolution in developing and transitioning countries*. <https://doi.org/10.2172/656842>
36. Munsamy, M., Telukdarie, A., Igusa, T., & Squire, M. M. (2023). Hospital energy demand forecasting for prioritisation during periods of constrained supply. *Journal of Industrial Engineering and Management*, 16(1), 131. <https://doi.org/10.3926/jiem.4229>

**HOW TO CITE:** Abhijit Dongardive\*, Salman Khan, Sagar Sirsat, Trupti Kokane, Akshay Jagtap, Leveraging Artificial Intelligence for Enhanced Pharmacy Practice: A Comprehensive Review, *Int. J. of Pharm. Sci.*, 2024, Vol 2, Issue 7, 742-749. <https://doi.org/10.5281/zenodo.12733016>

